Update on Phase I Adipose Stem Cell Trial

(Stem Cells News image)

Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.

Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.

This fat was processed to obtain the stromal vascular fraction (SVF) which contains mesenchymal stem cells, progenitor/endothelial cells, pericytes, hematopoetic stem cells and more.

The SVF was injected into the damaged areas of the heart using Bioheart’s MyoCath(R) catheter allowing for a minimally invasive delivery. Patients were followed on protocol for 6 months and demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their 6 minute walk distance (…)

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues.

Bioheart’s goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients (…)

read more:marketwatch.com/story/bioheart-inc-announces-update-on-phase-i-adipose-stem-cell-trial-2014-05-05

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.